RC
BIO icon

Rovin Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Rovin Capital’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,667
Closed -$548K – 179
2024
Q4 		$548K Sell
1,667
-332
-17% -$113K 0.2% 87
2024
Q3 		$669K Buy
+1,999
New +$635K 0.25% 91

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Rovin Capital's BIO Position: Q1 2025 in Review

Rovin Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2025, closing a stake of 1,667 shares — an estimated $548K sold.

Rovin Capital first reported a position in BIO in Q3 2024 and held it in 2 quarters. The position peaked at $669K in Q3 2024. 436 funds tracked by Wall St. Rank hold BIO as of Q1 2025.

  • Rovin Capital reported no remaining Bio-Rad Laboratories Class A position as of Q1 2025 after selling out during the quarter.
  • Rovin Capital sold 1,667 Bio-Rad Laboratories Class A shares in Q1 2025, an estimated $548K.
  • Rovin Capital first reported a position in Bio-Rad Laboratories Class A in Q3 2024 and held it in 2 quarters.
  • Rovin Capital's Bio-Rad Laboratories Class A position peaked at $669K in Q3 2024.
  • 436 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2025.

Based on Rovin Capital's 13F filing for Q1 2025, filed 28 Apr 2025.